stockrowQIAGEN N.V.
QGEN Healthcare Diagnostics & Research
QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024.
- Revenue
- +0.28%
- EPS
- +7.94%
- Free cash flow
- +30.5%
- Total debt
- +13.8%
Quarter to June 2026, against a year earlier
Follow QGEN
Alert me
QIAGEN N.V. (QGEN) Return on assets
QIAGEN N.V.'s return on assets over the twelve months to 30 June 2026 was 6.99%, down 0.1 percentage points from fiscal 2025 (7.10%). Over the past ten years it has ranged from −0.75% (fiscal 2019) to 8.53% (fiscal 2021); the current reading is higher than 91% of that period. That is above the Diagnostics & Research industry median of −6.05% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 7.10% | 5.68 |
| FY2024 | 1.42% | (4.08) |
| FY2023 | 5.50% | (1.31) |
| FY2022 | 6.81% | (1.72) |
| FY2021 | 8.53% | 2.06 |
| FY2020 | 6.47% | 7.22 |
| FY2019 | −0.75% | (4.28) |
| FY2018 | 3.53% | 2.67 |
| FY2017 | 0.86% | (1.03) |
| FY2016 | 1.89% | (1.12) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| MEDP Medpace Holdings, Inc. compare | 25.5% |
| BLLN BillionToOne, Inc. compare | 9.02% |
| QGEN QIAGEN N.V. | 6.99% |
| ICLR ICON PLC compare | 2.74% |
| RVTY Revvity Inc. compare | 2.14% |
| CRL Charles River Laboratories International, Inc. compare | 0.54% |
| RDNT RadNet, Inc. compare | −0.55% |
| GRAL GRAIL, Inc. compare | −15.2% |
| GH Guardant Health, Inc. compare | −30.7% |
| Diagnostics & Research industry median | −6.05% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on QGEN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement